Alexander Perl, MD, and James M. Foran, MD, FRCPC, prepared useful practice aids pertaining to leukemia for this CME activity titled "Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2EZE2I6. CME credit will be available until March 28, 2020.
Harry P. Erba, MD, PhD, and James M. Foran, MD, FRCPC, prepared useful Practice Aids pertaining to acute myeloid leukemia for this CME activity titled "The Continuing Wave of Innovation in AML: Getting the Most From the Convergence of Novel Therapy and Allogeneic Transplant." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2vdoO1j. CME credit will be available until March 12, 2021.
Harry P. Erba, MD, PhD, Naval Daver, MD, Courtney D. DiNardo, MD, MSCE, and Gail J. Roboz, MD prepared useful Practice Aids pertaining to acute myeloid leukemia for this CME/MOC activity titled Transforming Modern Care in AML: Clinical Solutions With Novel Agents for Diverse Patient Populations. For the full presentation, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3fsa7Jh. CME/MOC credit will be available until July 9, 2021.
Harry P. Erba, MD, PhD prepared useful practice aids pertaining to acute myeloid leukemia for this CME/MOC activity titled "Advances in AML Care: Highlights From Recent Science." For the full presentation, monograph, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2Xsu5x1. CME/MOC credit will be available until June 15, 2021.
Jorge E. Cortes, MD, and Stephen A. Strickland, MD, MSCI, prepared useful practice aids pertaining to acute myeloid leukemia for this CME activity titled "Novel Induction Options in AML: Assessing the Implications for HCT-Eligible Patients." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2u4yk5p. CME credit will be available until April 3, 2019.
Harry P. Erba, MD, PhD, and James M. Foran, MD, FRCPC, prepared useful Practice Aids pertaining to acute myeloid leukemia for this CME activity titled "The Continuing Wave of Innovation in AML: Getting the Most From the Convergence of Novel Therapy and Allogeneic Transplant." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2vdoO1j. CME credit will be available until March 12, 2021.
Harry P. Erba, MD, PhD, Naval Daver, MD, Courtney D. DiNardo, MD, MSCE, and Gail J. Roboz, MD prepared useful Practice Aids pertaining to acute myeloid leukemia for this CME/MOC activity titled Transforming Modern Care in AML: Clinical Solutions With Novel Agents for Diverse Patient Populations. For the full presentation, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3fsa7Jh. CME/MOC credit will be available until July 9, 2021.
Harry P. Erba, MD, PhD prepared useful practice aids pertaining to acute myeloid leukemia for this CME/MOC activity titled "Advances in AML Care: Highlights From Recent Science." For the full presentation, monograph, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2Xsu5x1. CME/MOC credit will be available until June 15, 2021.
Jorge E. Cortes, MD, and Stephen A. Strickland, MD, MSCI, prepared useful practice aids pertaining to acute myeloid leukemia for this CME activity titled "Novel Induction Options in AML: Assessing the Implications for HCT-Eligible Patients." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2u4yk5p. CME credit will be available until April 3, 2019.
EMPA-REG: un punto de inflexión en el tratamiento de la diabetes
18/11/15 20:00h Casa del Corazón (Madrid)
http://empareg.secardiologia.es
#EMPAREG
Resultados del estudio EMPA-REG
Dr. Domingo Marzal Martín, Complejo Hospitalario de Mérida (Badajoz)
@domingomarzal
SGLT2 Inhibitor therapy has opened up an exciting avenue for the Physicians to manage the patients with CKD . The slide set highlights the major trials on the drug showing remarkable benefits.
Co-Chairs Matthew S. Johnson, MD, FSIR, and Richard S. Finn, MD, and Laura M. Kulik, MD, prepared useful Practice Aids pertaining to hepatocellular carcinoma for this CME activity titled “At the Nexus of Locoregional and Systemic Liver Cancer Therapy: A Multidisciplinary Tumor Board on Improving Outcomes in Intermediate to Advanced HCC.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at http://bit.ly/2MrchQr. CME credit will be available until April 13, 2022.
Soap analysis on Coronary Artery Disease: By RxVichuZ!RxVichuZ
This powerpoint deals with Coronary Artery Disease, mentioning a few details into the disease & explaining the SOAP format of a patient having this disease(in short).
Regards,
@ RxVichu! :)
Naval Daver, MD, prepared useful practice aids pertaining to acute myeloid leukemia for this CME/CE activity titled "Groundbreaking Treatment Options for AML: How to Personalize Patient Care With New and Emerging Therapies." For the full presentation, monograph, complete CME/CE information, and to apply for credit, please visit us at http://bit.ly/2FCo09Y. CME/CE credit will be available until March 20, 2019.
Ghassan Abou-Alfa, MD, MBA, Anthony El-Khoueiry, MD, and R. Kate Kelley, MD, prepared useful Practice Aids pertaining to liver cancer for this CME/CE activity titled "Teaming Up to Improve Outcomes in Advanced Hepatocellular Carcinoma: A Tumor Board Evaluating the Potential of Immunotherapy and Novel Targeted Approaches." For the full presentation, monograph, complete CME/CE information, and to apply for credit, please visit us at http://bit.ly/2FG0J75. CME/CE credit will be available until March 25, 2019.
Amir T. Fathi, MD, Jenna Moran, NP, and Richard Dickens, MS, LCSW-R, prepared useful Practice Aids pertaining to acute myeloid leukemia for this CME/MOC/CNE activity titled "The Oncologist, Nurse, and Patient Partnership in AML: Multiple Perspectives on Integrating Targeted Therapy Into Care." For the full presentation, monograph, complete CME/MOC/CNE information, and to apply for credit, please visit us at http://bit.ly/2Dg4myq. CME/MOC/CNE credit will be available until December 4, 2019.
Richard S. Finn, MD, Anthony El-Khoueiry, MD, and Josep M. Llovet, MD, PhD, prepared useful practice aids pertaining to hepatocellular carcinoma for this CME activity titled "Breaking the Paradox: Expanding Options and New Questions in HCC Management: Mapping the Pathways to Better Patient Outcomes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2HU6L5K. CME credit will be available until February 14, 2020.
Richard Kim, MD, and Karon Martyn, MSN, ANP-BC, AOCNP, prepared useful Practice Aids pertaining to mCRC for this CME/MOC/CE activity titled "A Team Approach to Tackling the Complexities in Later Lines of Therapy for Metastatic Colorectal Cancer." For the full presentation, monograph, complete CME/MOC/CE information, and to apply for credit, please visit us at http://bit.ly/2IpIBz4. CME/MOC/CE credit will be available until May 29, 2019.
Author: Danielle Cassidy, PharmD, BCPS
Audience: Third year pharmacy students at University of Colorado School of Pharmacy & Oregon State University College of Pharmacy.
Background: Provides overview of common causes of pediatric venous thromboembolism & treatment management.
EMPA-REG: un punto de inflexión en el tratamiento de la diabetes
18/11/15 20:00h Casa del Corazón (Madrid)
http://empareg.secardiologia.es
#EMPAREG
Resultados del estudio EMPA-REG
Dr. Domingo Marzal Martín, Complejo Hospitalario de Mérida (Badajoz)
@domingomarzal
SGLT2 Inhibitor therapy has opened up an exciting avenue for the Physicians to manage the patients with CKD . The slide set highlights the major trials on the drug showing remarkable benefits.
Co-Chairs Matthew S. Johnson, MD, FSIR, and Richard S. Finn, MD, and Laura M. Kulik, MD, prepared useful Practice Aids pertaining to hepatocellular carcinoma for this CME activity titled “At the Nexus of Locoregional and Systemic Liver Cancer Therapy: A Multidisciplinary Tumor Board on Improving Outcomes in Intermediate to Advanced HCC.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at http://bit.ly/2MrchQr. CME credit will be available until April 13, 2022.
Soap analysis on Coronary Artery Disease: By RxVichuZ!RxVichuZ
This powerpoint deals with Coronary Artery Disease, mentioning a few details into the disease & explaining the SOAP format of a patient having this disease(in short).
Regards,
@ RxVichu! :)
Naval Daver, MD, prepared useful practice aids pertaining to acute myeloid leukemia for this CME/CE activity titled "Groundbreaking Treatment Options for AML: How to Personalize Patient Care With New and Emerging Therapies." For the full presentation, monograph, complete CME/CE information, and to apply for credit, please visit us at http://bit.ly/2FCo09Y. CME/CE credit will be available until March 20, 2019.
Ghassan Abou-Alfa, MD, MBA, Anthony El-Khoueiry, MD, and R. Kate Kelley, MD, prepared useful Practice Aids pertaining to liver cancer for this CME/CE activity titled "Teaming Up to Improve Outcomes in Advanced Hepatocellular Carcinoma: A Tumor Board Evaluating the Potential of Immunotherapy and Novel Targeted Approaches." For the full presentation, monograph, complete CME/CE information, and to apply for credit, please visit us at http://bit.ly/2FG0J75. CME/CE credit will be available until March 25, 2019.
Amir T. Fathi, MD, Jenna Moran, NP, and Richard Dickens, MS, LCSW-R, prepared useful Practice Aids pertaining to acute myeloid leukemia for this CME/MOC/CNE activity titled "The Oncologist, Nurse, and Patient Partnership in AML: Multiple Perspectives on Integrating Targeted Therapy Into Care." For the full presentation, monograph, complete CME/MOC/CNE information, and to apply for credit, please visit us at http://bit.ly/2Dg4myq. CME/MOC/CNE credit will be available until December 4, 2019.
Richard S. Finn, MD, Anthony El-Khoueiry, MD, and Josep M. Llovet, MD, PhD, prepared useful practice aids pertaining to hepatocellular carcinoma for this CME activity titled "Breaking the Paradox: Expanding Options and New Questions in HCC Management: Mapping the Pathways to Better Patient Outcomes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2HU6L5K. CME credit will be available until February 14, 2020.
Richard Kim, MD, and Karon Martyn, MSN, ANP-BC, AOCNP, prepared useful Practice Aids pertaining to mCRC for this CME/MOC/CE activity titled "A Team Approach to Tackling the Complexities in Later Lines of Therapy for Metastatic Colorectal Cancer." For the full presentation, monograph, complete CME/MOC/CE information, and to apply for credit, please visit us at http://bit.ly/2IpIBz4. CME/MOC/CE credit will be available until May 29, 2019.
Author: Danielle Cassidy, PharmD, BCPS
Audience: Third year pharmacy students at University of Colorado School of Pharmacy & Oregon State University College of Pharmacy.
Background: Provides overview of common causes of pediatric venous thromboembolism & treatment management.
Chair and Presenters Matthew D. Galsky, MD, Shilpa Gupta, MD, and Andrea Necchi, MD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC/AAPA/IPCE activity titled “Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3QlbwW0. CME/MOC/AAPA/IPCE credit will be available until February 26, 2025.
WHAT IS NEW IN MEDICINE TODAY?
Bangladesh Academy of Family Physicians organizes continuing medical education (CME) program last Friday of each month during 9AM to 12 noon. Part of this CME program is a 15-20 minutes presentation on "What is new in medicine today?" This presentation is prepared and presented exclusively by me.
To prepare this presentation I need to go through number of journals, recently released guidelines etc., collect specific information regarding newest researches and present.
Chair & Presenter, Robert Z. Orlowski, MD, PhD, Noa Biran, MD, and Ajay K. Nooka, MD, MPH, FACP, prepared useful Practice Aids pertaining to multiple myeloma for this CME/MOC/AAPA activity titled “The New ABCs of Myeloma Care: Enhancing Outcomes With CD38 Antibodies, BCMA Immunotherapy, and Unique Bispecific Platforms.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3MPq140. CME/MOC/AAPA credit will be available until July 3, 2024.
Sara M. Tinsley, PhD, APRN, AOCN and Laura J. Zitella, MS, RN, ACNP-BC, AOCN prepared useful practice aids pertaining to acute myeloid leukemia for this CNE activity titled Meeting the Many Challenges of AML: Oncology Nurse Tactics in an Era of Novel Therapies. For the full presentation, monograph, complete CNE information, and to apply for credit, please visit us at https://bit.ly/3f1qKLp. CNE credit will be available until August 9, 2021.
Co-Chairs Srdan Verstovsek, MD, PhD, and Ruben A. Mesa, MD, FACP, prepared useful Practice Aids pertaining to myelofibrosis for this CME activity titled “Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on Molecular Biology, JAK Inhibitors, and Emerging Therapeutics.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/3wzK6zG. CME credit will be available until October 9, 2022.
Chair and Moderator, Petros Grivas, MD, PhD, Shilpa Gupta, MD, and Gary D. Steinberg, MD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC activity titled “Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2WcJp3n. CME/MOC credit will be available until December 31, 2022.
Similar to Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance (20)
Co-Chairs Riad Salem, MD, MBA, and Mark Yarchoan, MD, discuss liver cancer in this CME/MOC activity titled “Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3IOQvQ6. CME/MOC credit will be available until June 14, 2025.
Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, prepared useful Practice Aids pertaining to non-cystic fibrosis bronchiectasis for this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.
Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, discuss non-cystic fibrosis bronchiectasis in this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.
Co-Chairs, Jonathan E. McConathy, MD, PhD, and Gil Rabinovici, MD, discuss Alzheimer's disease in this CME/AAPA activity titled “Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheimer’s Disease: Preparing Nuclear Medicine and Radiology Specialists for New Diagnostic Workflows.” For the full presentation, downloadable Practice Aids, and complete CME/AAPA information, and to apply for credit, please visit us at https://bit.ly/45RFl6g. CME/AAPA credit will be available until June 15, 2025.
Co-Chairs Sarah Hayward, PharmD, BCOP, and Ambar Khan, PharmD, BCOP, discuss endometrial and cervical cancers in this CME/CPE/IPCE activity titled “A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for Endometrial and Cervical Cancers: Insights on Coordinating and Delivering Effective Modern Care.” For the full presentation, downloadable Practice Aids, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at https://bit.ly/3wGBPQp. CME/CPE/IPCE credit will be available until May 27, 2025.
Co-Chairs, Suzanne Lentzsch, MD, PhD, and Joshua Richter, MD, discuss multiple myeloma in this CME activity titled “‘Four-Ward’ Progress in NDMM: New Developments With CD38 Antibody Quadruplets.” For the full presentation and complete CME information, and to apply for credit, please visit us at https://bit.ly/3x3oWA3. CME credit will be available until May 23, 2025.
Co-Chairs, Jessica Donington, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to lung cancer for this CME/MOC/AAPA activity titled “Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3TxdcP5. CME/MOC/AAPA credit will be available until June 7, 2025.
Co-Chairs, Jessica Donington, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, discuss lung cancer in this CME/MOC/AAPA activity titled “Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3TxdcP5. CME/MOC/AAPA credit will be available until June 7, 2025.
Chair Oliver Sartor, MD, discusses prostate cancer in this CME activity titled “On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic Strategies in Prostate Cancer.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/49oY4IJ. CME credit will be available until May 23, 2025.
Chair and Presenters, Neal D. Shore, MD, FACS, Ashish M. Kamat, MD, MBBS, and Joshua J. Meeks, MD, PhD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC/NCPD/AAPA/IPCE activity titled “Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3PH0RVQ. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 2, 2025.
Chair and Presenters, Neal D. Shore, MD, FACS, Ashish M. Kamat, MD, MBBS, and Joshua J. Meeks, MD, PhD, discuss bladder cancer in this CME/MOC/NCPD/AAPA/IPCE activity titled “Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3PH0RVQ. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 2, 2025.
Chair, Nicholas J. Short, MD, discusses acute lymphoblastic leukemia in this CME/NCPD/CPE/AAPA/IPCE activity titled “Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies & MRD-Guided Strategies Across Disease Settings.” For the full presentation, downloadable Practice Aids, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/42QsTDT. CME/NCPD/CPE/AAPA/IPCE credit will be available until May 22, 2025.
Chair, Sharon Cohen, MD, FRCPC, prepared useful Practice Aids pertaining to Alzheimer’s disease for this CME/MOC/AAPA activity titled “Specialty Training for the New Era in Alzheimer’s Disease: Building Skills for Making an Early Diagnosis and Implementing Disease-Modifying Treatment.” For the full presentation, downloadable Practice Aids, monograph, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/472bp8g. CME/MOC/AAPA credit will be available until May 20, 2025.
Chair, Sharon Cohen, MD, FRCPC, discusses Alzheimer’s disease in this CME/MOC/AAPA activity titled “Specialty Training for the New Era in Alzheimer’s Disease: Building Skills for Making an Early Diagnosis and Implementing Disease-Modifying Treatment.” For the full presentation, downloadable Practice Aids, monograph, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/472bp8g. CME/MOC/AAPA credit will be available until May 20, 2025.
Chair and Presenter, Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, Donna D. Catamero, ANP-BC, OCN, CCRC, and Charise Gleason, MSN, NP-C, AOCNP, discuss multiple myeloma in this CME/MOC/NCPD/ILNA/IPCE activity titled “Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/47mtUnM. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.
Co-Chairs and Presenter Marianne Davies, DNP, ACNP, AOCNP, FAAN, Beth Sandy, MSN, CRNP, FAPO, and Matthew A. Gubens, MD, MS, FASCO, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/NCPD/ILNA/IPCE activity titled “Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3RDokbZ. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 24, 2025.
Co-Chairs and Presenter Marianne Davies, DNP, ACNP, AOCNP, FAAN, Beth Sandy, MSN, CRNP, FAPO, and Matthew A. Gubens, MD, MS, FASCO, discuss NSCLC in this CME/MOC/NCPD/ILNA/IPCE activity titled “Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3RDokbZ. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 24, 2025.
Co-Chairs, Sia Daneshmand, MD, and Matthew D. Galsky, MD, discuss bladder cancer in this CME/MOC/NCPD/AAPA/IPCE activity titled “Modern Team-Based Therapeutic Management for Bladder Cancer Care: Expert Strategies for Integrating the Latest Evidence and Treatment Advances.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3OOeYbO. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 13, 2025.
Chair Jamie Carroll, APRN, CNP, MSN, discusses breast cancer in this NCPD/ILNA/AAPA activity titled “Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer: Best Practices for Adverse Event Management and Patient Education.” For the full presentation, downloadable Practice Aids, and complete NCPD/ILNA/AAPA information, and to apply for credit, please visit us at https://bit.ly/3SdnvWt. NCPD/ILNA/AAPA credit will be available until May 8, 2025.
Chair Jonathan A. Bernstein, MD, discusses chronic spontaneous urticaria in this CME activity titled “BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/3P0cnvi. CME credit will be available until May 6, 2025.
More from PVI, PeerView Institute for Medical Education (20)
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance
1. A Snapshot of Innovative Therapies in AML
Current Status, Dosing, and Other Considerations
PRACTICE AID
This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.
Access the activity,“Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance,”at
PeerView.com/PCE40.
STATUS DOSEDRUG CONSIDERATIONSTARGET
Approved
Plus chemotherapy in adults with newly
diagnosed FLT3-mutation–positive AML
50 mg orally twice daily with food on
d 8-21 of each induction cycle with
cytarabine and daunorubicin and on
d 8-21 of each consolidation cycle with
high-dose cytarabine
Midostaurin4
q GI events most common
q Promote therapy adherence
q Be mindful of potential drug–drug interactions
FLT3
Approved
Adults with R/R
IDH2-mutation–positive AML
100 mg orally daily
Enasidenib10
Monitor for:
q IDH-differentiation syndrome
q GI events
IDH2 q Elevated bilirubin
q Leukocytosis
Approved
Adults with R/R
IDH1-mutation–positive AML
500 mg orally daily
Ivosidenib11
Monitor for:
q IDH-differentiation syndrome
q Guillain-Barré syndrome
IDH1 q QT prolongation
q GI events, nausea,
leukocytosis
Breakthrough Therapy Designation
August 2018 (Under Priority Review)
Adults with newly diagnosed and R/R
FLT3-ITD–positive AML
60 mg used in phase 3 QuANTUM-R
study (30-mg lead-in)Quizartinib6-9
q Most common AEs in early studies included nausea,
prolonged QT interval, vomiting, and dysgeusia
FLT3
Approved
Adults with newly diagnosed
t-AML or AML-MRC
Induction: daunorubicin 44 mg/m2
and
cytarabine 100 mg/m2
liposome IV
over 90 min on d 1, 3, and 5a
CPX-3511-3
q Can cause prolongation of blood count suppression;
monitor blood counts regularly until recovery
q Not recommended in patients with decreased cardiac
function
Cytotoxic therapy
(liposomal cytarabine
+ daunorubicin
5:1 molar ratio)
Approved
Adults with FLT3-mutation–positive
R/R AML
120 mg orally daily
Gilteritinib5
q Most common AEs include myalgia/arthralgia,
transaminase increase, fatigue/malaise, noninfectious
diarrhea, dyspnea, edema, rash, pneumonia, nausea,
stomatitis, cough, headache, hypotension, dizziness,
and vomiting
FLT3
Approved
In combination with azacitidine or
decitabine or low-dose cytarabine for
newly diagnosed AML in adults
≥75 years or who have comorbidities
that preclude use of intensive
induction chemotherapy
BCL-2
Ramp-up phase: 100 mg orally on d 1,
200 mg on d 2, 400 mg on d 3;
d 4 and beyond: 400 mg (with HMA)
or 600 mg (with low-dose cytarabine)
q Most common AEs as part of combination therapy in
AML include nausea, diarrhea, thrombocytopenia,
constipation, neutropenia, febrile neutropenia, and
fatigue (among others)b
q Standard monitoring and prophylaxis measures for TLS
are recommended
Venetoclax12
2. a
For additional induction, use d 1 and 3 for subsequent cycles, if needed; for consolidation: daunorubicin 29 mg/m2
and cytarabine 65 mg/m2
liposome IV over 90 min on d 1 and 3. b
See prescribing information for a complete list of common AEs with venetoclax combinations in AML.12
AE: adverse event; AML: acute myeloid leukemia; AML-MRC: AML with myelodysplasia-related changes; BM: bone marrow; CD: cluster of differentiation; FLT3: fms-like tyrosine kinase 3; FN: febrile neutropenia; HCT: hematopoietic cell transplantation; Hhp: hedgehog pathway; HMA: hypomethylating
agent; IDH: isocitrate dehydrogenase; ITD: internal tandem duplication; mAb: monoclonal antibody; R/R: relapsed or refractory; t-AML: therapy-related acute myeloid leukemia; TLS: tumor lysis syndrome; VOD: veno-occlusive disease.
1. Lancet JE et al. 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO 2016). Abstract 7000. 2. Lancet JE et al. 2017 Annual BMT Tandem Meetings (BMT Tandem 2017). Abstract 19. 3. Vyxeos (daunorubicin and cytarabine) Prescribing Information. http://pp.jazzpharma.com/pi/vyxeos.
en.USPI.pdf. Accessed January 8, 2019. 4. Rydapt (midostaurin) Prescribing Information. https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/rydapt.pdf. Accessed January 8, 2019. 5. Xospata (gilteritinib) Prescribing Information. https://astellas.us/docs/xospata.pdf. Accessed
January 8, 2019. 6. https://clinicaltrials.gov/ct2/show/NCT02668653. Accessed January 8, 2019. 7. https://clinicaltrials.gov/ct2/show/NCT02039726. Accessed January 8, 2019. 8. Cortez J et al. 23rd Congress of the European Hematology Association (EHA 2018). Abstract LB2600. 9. https://pharmaphorum.
com/market-access-2/fda-grants-leukaemia-drug-breakthrough-status/. Accessed January 8, 2019. 10. Idhifa (enasidenib) Prescribing Information. https://media.celgene.com/content/uploads/idhifa-pi.pdf. Accessed January 8, 2019. 11. Tibsovo (ivosidenib) Prescribing Information. https://www.tibsovo.
com/pdf/prescribinginformation.pdf. Accessed January 8, 2019. 12. Venclexta (venetoclax) Prescribing Information. https://www.rxabbvie.com/pdf/venclexta.pdf. Accessed January 8, 2019. 13. Mylotarg (gemtuzumab ozogamicin) Prescribing Information. http://labeling.pfizer.com/ShowLabeling.
aspx?id=9548. Accessed January 8, 2019. 14. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm626443.htm. Accessed January 8, 2019. 15. Daurismo (glasdegib) Prescribing Information. http://labeling.pfizer.com/ShowLabeling.aspx?id=11336. Accessed January 8, 2019.
16. Agura E et al. 60th American Society of Hematology Annual Meeting and Exposition (ASH 2018). Abstract 1017. 17. Roboz GJ et al. FutureOncol. 2016;12:293-302.
Access the activity,“Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance,”at
PeerView.com/PCE40.
A Snapshot of Innovative Therapies in AML
Current Status, Dosing, and Other Considerations
PRACTICE AID
DRUG STATUS TARGET DOSE CONSIDERATIONS
Glasdegib14,15
Approved
In combination with low-dose cytarabine
for newly diagnosed AML in adults
≥75 years or who have comorbidities
that preclude use of intensive
induction chemotherapy
Hhp 100 mg orally daily
q Most common AEs include anemia, fatigue,
hemorrhage, FN, musculoskeletal pain, nausea,
edema, thrombocytopenia, and dyspnea
q See label for other common AEs and for information
on the potential for embryo-fetal toxicity and appropriate
management approaches
Gemtuzumab
ozogamicin13
Approved
Newly diagnosed CD33+ AML in adults,
R/R CD33+ AML in adults, and in
pediatric patients aged ≥2 years
CD33
Induction: 3 mg/m2
(up to one
4.5-mg vial) on d 1, 4, and 7 in
combination with daunorubicin
and cytarabine
q Infusion-related reactions
q Premedicate with corticosteroid, antihistamine,
and acetaminophen
q Monitor platelet counts frequently (hemorrhage) and
signs/symptoms of liver toxicity (VOD)
Phase 3 SIERRA study
Adults aged ≥55 years with active,
R/R AML, adequate organ function,
and related/unrelated matched donor
CD45
(BC8 mAb
linked to
radioisotope
iodine-131)
Dosimetry directed
(SIERRA study)
Iomab-B16
Phase 2 data
Maintenance therapy post-HCT in AML
Ongoing phase 3 QUAZAR study
Maintenance therapy in adults aged
≥55 years with AML in first complete
remission; HCT-ineligible AML
Epigenetic
modification
(novel oral
formulation
of HMA)
300 mg orally daily for 14 d of 28-d
treatment cycles (QUAZAR study)Oral
azacitidine17
q In phase 3 SIERRA trial, conditioning with Iomab-B
appeared feasible in patients with active disease and
high BM blast burden
q AEs included FN, stomatitis, malnutrition, epistaxis,
sepsis, hypotension, hypobilirubinemia, fatigue
q In early studies in the post-HCT maintenance setting,
grade 3/4 AEs included vomiting, thrombocytopenia,
diarrhea, and nausea
3. Access the activity,“Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance,”at
PeerView.com/PCE40.
Management of HCT-Eligible AML Patients
Induction, Post-Induction, and Post-Remission Therapy
PRACTICE AID
This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.
≥60 Years of Age1
<60 Years of Age1
Induction
• Standard-dose cytarabine + idarubicin or daunorubicin
• Standard-dose cytarabine + daunorubicin and cladribine
• High-dose cytarabine + idarubicin or daunorubicin
• Standard-dose cytarabine + daunorubicin and midostaurin
(FLT3-mutated AML)
• Liposomal encapsulation of cytarabine and daunorubicin (CPX-351) for
therapy-related AML other than CBF/APL, or patients with antecedent
MDS/CMML, or cytogenetic changes consistent with MDS
• Standard-dose cytarabine + daunorubicin and gemtuzumab ozogamicin
(CD33-positive)
• Fludarabine, high-dose cytarabine after fludarabine, idarubicin, and G-CSF
• Lower intensity therapy (HMAs preferred, low-dose
cytarabine)
• Gemtuzumab ozogamicin (CD33-positive)
• Enasidenib (IDH2-mutated AML) or ivosidenib
(IDH1-mutated AML)
• Venetoclax + decitabine
• Venetoclax + azacitidine
• Venetoclax + low-dose cytarabine
• Glasdegib + low-dose cytarabine
• BSC
• Additional standard-dose cytarabine + anthracycline or mitoxantrone
• Standard-dose cytarabine + daunorubicin and midostaurin
• Liposomal encapsulation of cytarabine and daunorubicin (CPX-351) for therapy-related
AML other than CBF/APL, or patients with antecedent MDS/CMML, or cytogenetic
changes consistent with MDS
• Intermediate-dose cytarabine–containing regimens
• Reduced-intensity allogeneic HCT
• Await recovery
• BSC
If significant cytoreduction with low % residual blasts
• Standard-dose cytarabine + idarubicin or daunorubicin
• Standard-dose cytarabine + daunorubicin and midostaurin
Post-Induction
Yes No
Unfavorable
Prognostic
Features?
Yes
No
(De novo
AML)
Hypoplasia
Residual
Disease
After Standard-Dose
Cytarabine in
Candidates for
Intensive Therapy
Await recovery
After
Standard-Dose
Cytarabine
After
High-Dose
Cytarabine
If significant residual disease
without a hypocellular marrow
• Matched sibling or
alternative donor HCT
• Therapy for R/R disease
• BSC
• Standard-dose cytarabine + idarubicin or daunorubicin or mitoxantrone
• Standard-dose cytarabine + daunorubicin and midostaurin (FLT3-mutated AML)
• Standard-dose cytarabine + daunorubicin and gemtuzumab ozogamicin (CD33-positive)
• Lower intensity therapy (HMAs)
• Venetoclax + decitabine
• Venetoclax + azacitidine
• Standard-dose cytarabine + idarubicin or daunorubicin or mitoxantrone
• Standard-dose cytarabine + daunorubicin and midostaurin (FLT3-mutated AML)
• Liposomal encapsulation of cytarabine and daunorubicin (CPX-351) for therapy-related AML
other than CBF/APL, or patients with antecedent MDS/CMML, or cytogenetic changes that are
consistent with MDS
Clinical note: Novel therapeutics currently being assessed in the HCT setting in AML include the radioimmunoconjugate Iomab-B (as pretransplant conditioning)2
and oral azacitidine as an HMA maintenance option.3
If significant residual disease without a hypocellular marrow
• Cytarabine
• Standard-dose cytarabine + idarubicin or daunorubicin
• Standard-dose cytarabine + daunorubicin and midostaurin
• Liposomal encapsulation of cytarabine and daunorubicin (CPX-351) for
therapy-related AML other than CBF/APL, or patients with antecedent
MDS/CMML, or cytogenetic changes consistent with MDS
Candidate
for Intensive
Therapy?
4. AML: acute myeloid leukemia; APL: acute promyelocytic leukemia; BSC: best supportive care; CBF: core-binding factor; CD: cluster of differentiation; CMML: chronic myelomonocytic leukemia; FLT3: fms-like tyrosine kinase 3; G-CSF: granulocyte colony-stimulating factor; HCT: hematopoietic
cell transplantation; HMAs: hypomethylating agents; IDH2: isocitrate dehydrogenase 2; MDS: myelodysplastic syndrome; PS: performance status.
1. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia. Version 3.2018. 2. Agura E et al. 60th American Society of Hematology Annual Meeting and Exposition (ASH 2018). Abstract 1017. 3. Roboz GJ et al. Future Oncol. 2016;12:293-302.
Access the activity,“Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance,”at
PeerView.com/PCE40.
Management of HCT-Eligible AML Patients
Induction, Post-Induction, and Post-Remission Therapy
PRACTICE AID
≥60 Years of Age1
<60 Years of Age1
• Matched sibling/alternative donor HCT
• High-dose cytarabine
• High-dose cytarabine and midostaurin (FLT3-mutated AML)
• Liposomal encapsulation of cytarabine and daunorubicin
(CPX-351) for therapy-related AML other than CBF/APL, or
patients with antecedent MDS/CMML, or cytogenetic changes
consistent with MDS• BSC
Post-Remission(Consolidation)Therapy
Previous
Intensive
Therapy
Yes
Yes
No
No
Response?
Previous
Low-Intensity
Therapy
Poor-Risk
Cytogenetics/
Molecular
Abnormalities
• Reduced-intensity HCT
• Standard-dose cytarabine ± anthracycline (idarubicin or daunorubicin)
• Consider intermediate-dose cytarabine in patients with good PS, normal renal function,
and better-risk or normal karyotype with favorable molecular markers
• Intermediate-dose cytarabine with midostaurin
• Liposomal encapsulation cytarabine and daunorubicin (CPX-351) for therapy-related
AML other than CBF/APL, or patients with antecedent MDS/CMML, or cytogenetic
changes consistent with MDS
• Cytarabine 1,000 mg/m2
+ daunorubicin + gemtuzumab ozogamicin (CD33-positive)
• Maintenance with HMAs until progression (if patient received HMAs during induction)
• Observation
Induction failure
• Allogeneic HCT (preferably in clinical trial)
• BSC
CBF
Translocations
Treatment-
Related
DiseaseOr
Complete
Response?
• High-dose cytarabine
• Cytarabine 1,000 mg/m2
+ daunorubicin and gemtuzumab
ozogamicin (CD33-positive)
No KIT Mutation
or Favorable Risk
Molecular
Abnormalities
• Matched sibling or alternative donor HCT
• High-dose cytarabine
• High-dose cytarabine and midostaurin (FLT3-mutated AML)
• Cytarabine 1,000 mg/m2
+ daunorubicin and gemtuzumab
ozogamicin (CD33-positive)
Intermediate-Risk
Cytogenetics/
Molecular
Abnormalities
• Reduced-intensity HCT
• Continued HMA therapy every 4-6 wk until progression
• Gemtuzumab ozogamicin (CD33-positive)
• Continue enasidenib or ivosidenib until progression (IDH2-mutated AML)
• Continue venetoclax + decitabine
• Continue venetoclax + low-dose cytarabine
• Continue glasdegib + low-dose cytarabine